Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast - Seagen (NASDAQ:SGEN), Pfizer (NYSE:PFE)

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Pfizer, Inc. (NYSE: PFE), 

Related Keywords

Robyn Karnauskas ,Seagen Inc ,Pfizer ,Pfizer Inc ,